Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data
- Submitting institution
-
The University of East Anglia
- Unit of assessment
- 11 - Computer Science and Informatics
- Output identifier
- 182621344
- Type
- D - Journal article
- DOI
-
10.1371/journal.pgen.1007001
- Title of journal
- PLoS Genetics
- Article number
- e1007001
- First page
- -
- Volume
- 13
- Issue
- 9
- ISSN
- 1553-7404
- Open access status
- Compliant
- Month of publication
- September
- Year of publication
- 2017
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
55
- Research group(s)
-
-
- Citation count
- 16
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- A novel analytic recurrent copy number pipeline was developed and compared with the established tool. This pipeline is being used in a large-scale trial to determine the best way of treating men with newly diagnosed advanced prostate cancer (STAMPEDE; UCL). The new prostate drug targets identified are of interest to pharmaceutical researchers e.g. Genetics in Medicine 22(3), pp. 538-546. This paper challenged the established dogma of how genes are knocked out in prostate cancer (cited in 15 papers). This work was funded by a CRUK grant (C5047/A14835) and supporting the successful funding of project grant (CRUK C5047/A2253; £1.6M).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -